GB0122318D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0122318D0
GB0122318D0 GBGB0122318.9A GB0122318A GB0122318D0 GB 0122318 D0 GB0122318 D0 GB 0122318D0 GB 0122318 A GB0122318 A GB 0122318A GB 0122318 D0 GB0122318 D0 GB 0122318D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
periocular
embedded
pharmacologically acceptable
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0122318.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0122318.9A priority Critical patent/GB0122318D0/en
Publication of GB0122318D0 publication Critical patent/GB0122318D0/en
Priority to ES02779354T priority patent/ES2302849T3/es
Priority to MXPA04002421A priority patent/MXPA04002421A/es
Priority to JP2003528517A priority patent/JP2005504797A/ja
Priority to IL16002702A priority patent/IL160027A0/xx
Priority to RU2004111596/15A priority patent/RU2316315C2/ru
Priority to EP02779354A priority patent/EP1429725B1/en
Priority to CN2010105534172A priority patent/CN102008428A/zh
Priority to KR10-2004-7001255A priority patent/KR20040030869A/ko
Priority to PCT/EP2002/010314 priority patent/WO2003024420A1/en
Priority to AT02779354T priority patent/ATE389385T1/de
Priority to CA2455680A priority patent/CA2455680C/en
Priority to PL368128A priority patent/PL203949B1/pl
Priority to HK04109814.1A priority patent/HK1066733B/en
Priority to NZ531481A priority patent/NZ531481A/en
Priority to DE60225701T priority patent/DE60225701T2/de
Priority to AU2002342694A priority patent/AU2002342694B2/en
Priority to CNA028155742A priority patent/CN1538835A/zh
Priority to US10/489,752 priority patent/US20040234611A1/en
Priority to HU0401568A priority patent/HU229453B1/hu
Priority to PT02779354T priority patent/PT1429725E/pt
Priority to BR0212475-0A priority patent/BR0212475A/pt
Priority to IL160027A priority patent/IL160027A/en
Priority to ZA200400524A priority patent/ZA200400524B/en
Priority to EC2004004967A priority patent/ECSP044967A/es
Priority to CO04013821A priority patent/CO5560548A2/es
Priority to NO20040917A priority patent/NO333825B1/no
Priority to US12/194,617 priority patent/US20080305172A1/en
Priority to JP2010224231A priority patent/JP2011026338A/ja
Priority to US13/523,537 priority patent/US20120269894A1/en
Priority to US13/735,076 priority patent/US20130122064A1/en
Priority to JP2013099024A priority patent/JP2013147516A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0122318.9A 2001-09-14 2001-09-14 Organic compounds Ceased GB0122318D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB0122318.9A GB0122318D0 (en) 2001-09-14 2001-09-14 Organic compounds
BR0212475-0A BR0212475A (pt) 2001-09-14 2002-09-13 Composições farmacêuticas
NZ531481A NZ531481A (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
DE60225701T DE60225701T2 (de) 2001-09-14 2002-09-13 Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichung
JP2003528517A JP2005504797A (ja) 2001-09-14 2002-09-13 眼周囲または結膜下投与のための眼用デポー製剤
IL16002702A IL160027A0 (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
RU2004111596/15A RU2316315C2 (ru) 2001-09-14 2002-09-13 Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
EP02779354A EP1429725B1 (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
CN2010105534172A CN102008428A (zh) 2001-09-14 2002-09-13 用于眼周或结膜下施用的眼长效制剂
KR10-2004-7001255A KR20040030869A (ko) 2001-09-14 2002-09-13 안구주위 또는 결막하부 투여를 위한 안과용 데포 제제
CNA028155742A CN1538835A (zh) 2001-09-14 2002-09-13 用于眼周或结膜下施用的眼长效制剂
AT02779354T ATE389385T1 (de) 2001-09-14 2002-09-13 Ophthalmische depot-formulierungen zur periokkularen oder subkonjunktivalen verabreichung
CA2455680A CA2455680C (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
PL368128A PL203949B1 (pl) 2001-09-14 2002-09-13 Zastosowanie preparatu oftalmicznego do wytwarzania leku typu depot do podawania okołoocznego
HK04109814.1A HK1066733B (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
ES02779354T ES2302849T3 (es) 2001-09-14 2002-09-13 Formulaciones oftalmicas de deposito para la administracion periocular o subconjuntival.
AU2002342694A AU2002342694B2 (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
US10/489,752 US20040234611A1 (en) 2001-09-14 2002-09-13 Ophthalmic deport formulations for periocular or subconjunctival administration
PCT/EP2002/010314 WO2003024420A1 (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
MXPA04002421A MXPA04002421A (es) 2001-09-14 2002-09-13 Formulaciones de deposito oftalmicas para administracion periocular o subconjuntival.
HU0401568A HU229453B1 (en) 2001-09-14 2002-09-13 Ophthalmic depot formulations for periocular or subconjunctival administration
PT02779354T PT1429725E (pt) 2001-09-14 2002-09-13 Formulações oftálmicas de depósito para administração subconjuntival ou periocular
IL160027A IL160027A (en) 2001-09-14 2004-01-22 Ophthalmic depot formulations for periocular or subconjunctival administration and use thereof in the manufacture of medicaments for treating ocular diseases
ZA200400524A ZA200400524B (en) 2001-09-14 2004-01-23 Ophthalmic depot formulations for periocular or subconjunctival administration.
EC2004004967A ECSP044967A (es) 2001-09-14 2004-02-02 Formulaciones de deposito oftalmicas para administracion periocular o subconjuntival
CO04013821A CO5560548A2 (es) 2001-09-14 2004-02-18 Formulaciones de deposito oftalmicas para administracion periocular o subconjuntival
NO20040917A NO333825B1 (no) 2001-09-14 2004-03-02 Anvendelse av oftalmologisk formulering for fremstilling av et depotpreparat for periokular administrering
US12/194,617 US20080305172A1 (en) 2001-09-14 2008-08-20 Ophthalmic depot formulations for periocular or suconjunctival administration
JP2010224231A JP2011026338A (ja) 2001-09-14 2010-10-01 眼周囲または結膜下投与のための眼用デポー製剤
US13/523,537 US20120269894A1 (en) 2001-09-14 2012-06-14 Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration
US13/735,076 US20130122064A1 (en) 2001-09-14 2013-01-07 Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration
JP2013099024A JP2013147516A (ja) 2001-09-14 2013-05-09 眼周囲または結膜下投与のための眼用デポー製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0122318.9A GB0122318D0 (en) 2001-09-14 2001-09-14 Organic compounds

Publications (1)

Publication Number Publication Date
GB0122318D0 true GB0122318D0 (en) 2001-11-07

Family

ID=9922147

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0122318.9A Ceased GB0122318D0 (en) 2001-09-14 2001-09-14 Organic compounds

Country Status (24)

Country Link
US (4) US20040234611A1 (https=)
EP (1) EP1429725B1 (https=)
JP (3) JP2005504797A (https=)
KR (1) KR20040030869A (https=)
CN (2) CN102008428A (https=)
AT (1) ATE389385T1 (https=)
AU (1) AU2002342694B2 (https=)
BR (1) BR0212475A (https=)
CA (1) CA2455680C (https=)
CO (1) CO5560548A2 (https=)
DE (1) DE60225701T2 (https=)
EC (1) ECSP044967A (https=)
ES (1) ES2302849T3 (https=)
GB (1) GB0122318D0 (https=)
HU (1) HU229453B1 (https=)
IL (2) IL160027A0 (https=)
MX (1) MXPA04002421A (https=)
NO (1) NO333825B1 (https=)
NZ (1) NZ531481A (https=)
PL (1) PL203949B1 (https=)
PT (1) PT1429725E (https=)
RU (1) RU2316315C2 (https=)
WO (1) WO2003024420A1 (https=)
ZA (1) ZA200400524B (https=)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
CA2536185C (en) * 2003-08-20 2012-06-26 Santen Pharmaceutical Co., Ltd. Drug delivery system by administrating fine particles to sub-tenon
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
JP2006257080A (ja) * 2005-02-18 2006-09-28 Santen Pharmaceut Co Ltd ステロイド化合物の副作用軽減または回避方法
US8440217B1 (en) * 2005-06-15 2013-05-14 Mawaheb M. EL-Naggar Method and system with contact lens product for treating and preventing adverse eye conditions
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
CA2623239C (en) 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
RU2456979C1 (ru) * 2011-04-11 2012-07-27 Общество с ограниченной ответственностью "ЭкоБиоФармДубна" Индометацин на основе фосфолипидных наночастиц для применения в офтальмологии
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
RU2672596C2 (ru) * 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CA3169368A1 (en) * 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2907770C (en) 2013-03-22 2022-02-15 Nova Southeastern University Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
MY196111A (en) 2014-07-18 2023-03-15 Allergan Inc Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
RU2616258C2 (ru) * 2014-11-10 2017-04-13 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Способ получения полимерных наночастиц низкосиалированного эритропоэтина с высокой степенью сорбции для лечения неврологических заболеваний
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
CN107635545A (zh) 2015-01-27 2018-01-26 约翰霍普金斯大学 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3866773B1 (en) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
JP7657457B2 (ja) 2018-10-19 2025-04-07 ノバ サウスイースタン ユニバーシティー ｐＨ修飾賦形剤及び浸入促進剤を含む舌下エピネフリン組成物及びそれを使用する方法
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
WO2021087399A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
US12577398B2 (en) 2019-11-12 2026-03-17 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物
WO2021168320A1 (en) 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2022066774A1 (en) 2020-09-23 2022-03-31 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
BE788575A (fr) * 1971-09-09 1973-01-02 Alza Corp Dispositif oculaire pour l'administration d'un
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
GB1425550A (en) * 1973-04-25 1976-02-18 Alza Corp Device for releasing active agent and process for producing the same
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3722837A1 (de) * 1987-07-10 1989-01-19 Ruetgerswerke Ag Ophthalmisches depotpraeparat
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU640232B2 (en) * 1990-04-27 1993-08-19 Allergan, Inc. Polymeric drug delivery system
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
IL113112A (en) * 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
WO2000009098A2 (en) * 1998-08-13 2000-02-24 Novartis Ag Method for treating ocular neovascular diseases
BR9915569A (pt) * 1998-11-23 2001-08-14 Novartis Ag Método para o tratamento de doenças neovasculares oculares
CZ20023174A3 (cs) * 2000-03-24 2003-01-15 Novartis Ag Farmaceutické prostředky obsahující antiangiogenní léčivo a fotosenzitivní činidlo
US20040115236A1 (en) * 2000-10-06 2004-06-17 Chan Tai Wah Devices and methods for management of inflammation
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction

Also Published As

Publication number Publication date
CA2455680A1 (en) 2003-03-27
RU2004111596A (ru) 2005-04-20
US20080305172A1 (en) 2008-12-11
ZA200400524B (en) 2004-11-17
BR0212475A (pt) 2004-08-24
HU229453B1 (en) 2013-12-30
JP2005504797A (ja) 2005-02-17
JP2013147516A (ja) 2013-08-01
CN1538835A (zh) 2004-10-20
PL203949B1 (pl) 2009-11-30
US20120269894A1 (en) 2012-10-25
HUP0401568A2 (hu) 2004-11-29
ATE389385T1 (de) 2008-04-15
JP2011026338A (ja) 2011-02-10
CO5560548A2 (es) 2005-09-30
US20130122064A1 (en) 2013-05-16
HK1066733A1 (en) 2005-04-01
CA2455680C (en) 2010-07-20
PT1429725E (pt) 2008-06-18
WO2003024420A1 (en) 2003-03-27
IL160027A0 (en) 2004-06-20
KR20040030869A (ko) 2004-04-09
NZ531481A (en) 2005-12-23
NO333825B1 (no) 2013-09-23
ES2302849T3 (es) 2008-08-01
NO20040917L (no) 2004-03-02
DE60225701D1 (de) 2008-04-30
DE60225701T2 (de) 2009-04-30
HUP0401568A3 (en) 2008-04-28
EP1429725A1 (en) 2004-06-23
US20040234611A1 (en) 2004-11-25
ECSP044967A (es) 2004-03-23
MXPA04002421A (es) 2004-05-31
CN102008428A (zh) 2011-04-13
EP1429725B1 (en) 2008-03-19
PL368128A1 (en) 2005-03-21
IL160027A (en) 2009-11-18
AU2002342694B2 (en) 2006-08-24
RU2316315C2 (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
GB0122318D0 (en) Organic compounds
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
IL153297A0 (en) Compounds and compositions for delivering active agents
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
WO2002024184A3 (de) Mechanisch stabile darreichungsformen, enthaltend ubichinone
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2006138735A3 (en) Gel compositions for topical administration
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2006024284A3 (de) Atrium patch
WO2002004012A8 (en) Anhydrous pharmaceutical composition of vancomycin for topical use
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)